Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FRANCISCO GELPI-HAMMERSCHMIDT

Allopathic & Osteopathic Physicians Urology

NPI
1821245655
CMS profile
1155804
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$8,286.74

114 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FRANCISCO GELPI-HAMMERSCHMIDT

NPI 1821245655 · CMS profile ID 1155804

Allopathic & Osteopathic Physicians / Urology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821245655?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FRANCISCO GELPI-HAMMERSCHMIDT, NPI 1821245655, CMS profile ID 1155804. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821245655?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). FRANCISCO GELPI-HAMMERSCHMIDT, NPI 1821245655, CMS profile ID 1155804. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821245655?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
FRANCISCO GELPI-HAMMERSCHMIDT, NPI 1821245655, CMS profile ID 1155804, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1821245655?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

114 matching records · $8,286.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 114 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–114 of 114.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Kowa Pharmaceuticals America, Inc. $15.3402/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003761115 CMS
ABBVIE INC. $20.1902/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997329867 CMS
Myriad Genetic Laboratories, Inc. $17.5502/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059774443 CMS
Sumitomo Pharma America, Inc. $6.1702/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030934387 CMS
180 Medical, Inc. $20.9702/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057527577 CMS
Sumitomo Pharma America, Inc. $5.6201/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030934391 CMS
Astellas Pharma US Inc $12.8901/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033887325 CMS
PFIZER INC. $22.5701/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049121777 CMS
AngioDynamics, Inc. $16.2401/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025284421 CMS
Endo Pharmaceuticals Inc. $24.6001/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033328425 CMS
ACCORD HEALTHCARE, INC. $19.8101/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052300439 CMS
AngioDynamics, Inc. $10.1301/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025284419 CMS
Bayer Healthcare Pharmaceuticals Inc. $23.5901/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000892890 CMS
Alnylam Pharmaceuticals Inc. $25.7401/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006132841 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,181.95 40
PY2020 $433.11 19
PY2021 $722.76 24
PY2022 $5,705.58 66
PY2023 $8,286.74 114
PY2024 $2,605.02 72
PY2025 $8,073.58 100

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $156,330.08 26
PY2024 Principal investigator $219,436.80 21
PY2023 Principal investigator $33,355.45 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,503.00 12/29/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175373967
Principal investigator 1 Janssen Research & Development, LLC $12,874.00 12/29/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175374058
Principal investigator 1 Janssen Research & Development, LLC $3,945.00 11/07/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175374200
Principal investigator 1 Janssen Research & Development, LLC $6,762.00 11/03/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175374216
Principal investigator 1 Janssen Research & Development, LLC $9,675.00 10/02/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175373976
Principal investigator 1 Janssen Research & Development, LLC $4,782.00 09/08/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175373959
Principal investigator 1 Janssen Research & Development, LLC $704.00 09/08/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175374028
Principal investigator 1 Janssen Research & Development, LLC $3,314.00 08/11/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175374069
Principal investigator 1 Janssen Research & Development, LLC $23,760.00 07/30/2025 Non-covered Recipient Entity
Houston Metro Uro
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175282063
Principal investigator 1 Janssen Research & Development, LLC $16,594.00 07/28/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175374191
Principal investigator 1 Janssen Research & Development, LLC $1,210.00 07/07/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175374128
Principal investigator 1 Janssen Research & Development, LLC $4,722.00 07/04/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175374225
Principal investigator 1 Janssen Research & Development, LLC $8,212.00 06/30/2025 Non-covered Recipient Entity
HMU CRC LLC
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175373995
Principal investigator 1 Sumitomo Pharma America, Inc. $2,850.00 06/18/2025 Non-covered Recipient Entity
HMU CRC LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176636404
Principal investigator 1 Janssen Research & Development, LLC $5,687.00 06/06/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175373989
Principal investigator 1 Janssen Research & Development, LLC $704.00 05/12/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175374035
Principal investigator 1 Janssen Research & Development, LLC $5,687.00 04/28/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175374104
Principal investigator 1 Janssen Research & Development, LLC $704.00 04/07/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175374089
Principal investigator 1 Janssen Research & Development, LLC $10,708.00 03/10/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175374051
Principal investigator 1 Janssen Research & Development, LLC $4,986.00 03/10/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175374175
Principal investigator 1 Sumitomo Pharma America, Inc. $4,970.88 02/26/2025 Non-covered Recipient Entity
HMU CRC LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176628559
Principal investigator 1 Janssen Research & Development, LLC $2,122.00 02/14/2025 Non-covered Recipient Entity
Houston Metro Uro
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175282238
Principal investigator 1 Janssen Research & Development, LLC $6,953.00 02/10/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175374209
Principal investigator 1 Janssen Research & Development, LLC $1,528.00 02/03/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175374158
Principal investigator 1 Sumitomo Pharma America, Inc. $4,841.20 01/29/2025 Non-covered Recipient Entity
HMU CRC LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176624953
Principal investigator 1 Janssen Research & Development, LLC $6,532.00 01/02/2025 Non-covered Recipient Entity
HMU CRC LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175374082

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $3,703.71 1
PY2025 Value of interest $3,703.71 1
PY2024 Amount invested $3,703.71 1
PY2024 Value of interest $3,703.71 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

2 records · PY2024–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 HMU Consumables, LLC $3,703.71 $3,703.71 LLC Membership Interest Physician Covered Recipient No dispute reported 06/30/2026 1188127824
PY2024 HMU Consumables, LLC $3,703.71 $3,703.71 LLC Membership Interest Physician Covered Recipient No dispute reported 06/30/2026 1123574678